The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer

被引：0
|
作者：
Boer R.
机构：
来源：
Breast Cancer Research | / 1卷 / 1期
关键词：
HER-2; Metastatic breast cancer; Monoclonal antibody;
D O I：
10.1186/bcr-1999-66610
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
相关论文
共 50 条
  • [31] Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer
    Shojima, K.
    Suzuki, E.
    Saito, K.
    Sekine, S.
    Kitagawa, D.
    Aruga, T.
    Saji, S.
    Kuroi, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Influence of trastuzumab on the incidence of brain metastasis in patients with Her2-overexpressing metastatic breast cancer
    Massard, C.
    Brain, E.
    Dunan, A.
    Mathieu, M.
    Guinebretiere, J.
    Abuin, G. Gomez
    Floiras, J.
    Spielmann, M.
    Delaloge, S.
    Andre, F.
    EJC SUPPLEMENTS, 2005, 3 (02): : 119 - 120
  • [33] Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates
    Savellano, MD
    Pogue, BW
    Hoopes, PJ
    Vitetta, ES
    Paulsen, KD
    CANCER RESEARCH, 2005, 65 (14) : 6371 - 6379
  • [34] Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2-Overexpressing Metastatic Breast Cancer
    Huang, Yuan
    Fu, Peifen
    Fan, Weimin
    CURRENT DRUG TARGETS, 2013, 14 (08) : 889 - 898
  • [35] Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer
    Laginha, Kimberley M.
    Moase, Elaine H.
    Yu, Ning
    Huang, Anthony
    Allen, T. M.
    JOURNAL OF DRUG TARGETING, 2008, 16 (7-8) : 605 - 610
  • [36] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Rugo, Hope S.
    Chien, A. Jo
    Franco, Sandra X.
    Stopeck, Alison T.
    Glencer, Alexa
    Lahiri, Soumi
    Arbushites, Michael C.
    Scott, Janet
    Park, John W.
    Hudis, Clifford
    Nulsen, Ben
    Dickler, Maura N.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 13 - 20
  • [37] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Hope S. Rugo
    A. Jo Chien
    Sandra X. Franco
    Alison T. Stopeck
    Alexa Glencer
    Soumi Lahiri
    Michael C. Arbushites
    Janet Scott
    John W. Park
    Clifford Hudis
    Ben Nulsen
    Maura N. Dickler
    Breast Cancer Research and Treatment, 2012, 134 : 13 - 20
  • [38] PIPERINE DOWNREGULATES HER2 EXPRESSION, LEADING TO INHIBITION OF HER2-MEDIATED PROLIFERATION, MIGRATION AND APOPTOSIS POTENTIALS IN HER2-OVEREXPRESSING BREAST CANCER CELLS
    Kim, Hyung Gyun
    Minh Truong Do
    Jeong, Hye Gwang
    DRUG METABOLISM REVIEWS, 2014, 45 : 59 - 59
  • [39] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Clara Natoli
    Patrizia Vici
    Isabella Sperduti
    Antonino Grassadonia
    Giancarlo Bisagni
    Nicola Tinari
    Andrea Michelotti
    Germano Zampa
    Stefania Gori
    Luca Moscetti
    Michele De Tursi
    Michele Panebianco
    Maria Mauri
    Ilaria Ferrarini
    Laura Pizzuti
    Corrado Ficorella
    Riccardo Samaritani
    Lucia Mentuccia
    Stefano Iacobelli
    Teresa Gamucci
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1229 - 1240
  • [40] Prognostic Value of Basal Phenotype in HER2-overexpressing Breast Cancer
    Sanjay P. Bagaria
    Partha S. Ray
    Jinhua Wang
    Luisa Kropcho
    Alice Chung
    Myung-Shin Sim
    Jaime M. Shamonki
    Silvana Martino
    Xiaojiang Cui
    Armando E. Giuliano
    Annals of Surgical Oncology, 2012, 19 : 935 - 940
12345